The dopamine receptor D2 (DRD2) gene has polymorphisms that have been linked to regulation of the dopamine system and to an increased prevalence of smoking. The present study examined the relationship of the DRD2 TaqI-A and -B polymorphisms with short-term clinical outcome (abstinence and withdrawal symptoms), collected from daily (14 pre-quit and 42 post-quit) diary data among smokers (n ¼ 116) treated with the nicotine patch plus either venlafaxine or placebo. The results showed that B1/B1 or B1/B2 smokers were slightly less likely to be abstinent on a given day than those homozygous for the TaqI-B2 allele. Significant DRD2 TaqI-B Â time interactions were found for several of the withdrawal scales, indicating that those smokers with the B1/B1 or B1/B2 genotypes tended to report more symptoms over time compared to those with the B2/B2 genotype. No interactions or main effects were found for the DRD2 TaqI-A polymorphism. The findings demonstrate that smokers homozygous for the TaqI-B2 allele experience progressive improvement in self-reported withdrawal symptoms while smokers with the TaqI-B1 allele showing little change.
Introduction
Nicotine, along with a number of substances that share the potential for abuse, enhances dopamine activity in mesolimbic and mesocortical circuits thought to be important for behavioral reward and reinforcement. 1 The role of genetic factors in these dopaminergic pathways are of interest in identifying risk factors for addiction (e.g., [2] [3] [4] ). Many genes are involved in the regulation of the dopamine system, and the DRD2 gene is one of the most frequently studied in addictive disorders.
The human dopamine receptor D2 (DRD2) gene is located on chromosome 11q22-q23. Several polymorphisms in DRD2 have been described, including the TaqI-A restriction fragment length polymorphism (RFLP) located in the 3 0 flanking region 10 000 nucleotide pairs distal from the coding region of DRD2, and the TaqI-B RFLP, located in intron 1, 913 nucleotide pairs from the start codon in exon 2, and closer to the 5 0 regulatory region of the DRD2 than the more 3 0 TaqI-A. 5 Recent findings, however, now place the TaqI-A polymorphism within an exon of an adjacent new protein kinase gene called 'ankyrin repeat and kinase domain containing 1' (ANKK1), which may influence signal transduction 7 although not with the À141C Ins/Del polymorphism. 8 The C957T and the À141C Ins/Del are functional alleles in the DRD2 gene that have been associated with mRNA stability and expression.
Both the TaqI-A1 9-11 and -B1 10 alleles have been associated with a decrease in D2 dopamine receptor density in the striatum, presumably conferring a reward deficiency that might increase substance use in an effort to offset the deficit. A recent meta-analysis suggested a significant role of the TaqI-A1 allele in smoking behavior, initiation of smoking, persistence of smoking and cigarette consumption, 12 whereas a second meta-analysis found a significantly higher prevalence of the TaqI-A1 allele in smokers vs nonsmokers. 13 In addition to the TaqI-A1 allele, the TaqI-B1 allele has also been linked to increased prevalence of smoking. For example, several studies have reported higher prevalence rates of the TaqI-A1 or TaqI-B1 allele in current and former smokers vs non-smokers. [14] [15] [16] Pastorelli et al. 17 noted that the TaqI-B1 allele was more common among non-alcoholic smokers than the matched non-alcoholic non-smokers. An epidemiological study in Caucasian lung cancer patients reported that ever-smokers had a fourfold increase in the presence of the TaqI-B1 allele compared to never-smokers in both the cancer patients and controls. 16 Additionally, the age of onset of smoking behavior was earlier in those patients with the TaqI-A1 or -B1 allele and they made fewer lifetime attempts to quit smoking than those patients without those alleles. 16 Lastly, a study involving Mexican-American and African-American participants reported greater frequency of smoking-related cancers among first-degree relatives of case subjects with the TaqI-A1 or -B1 allele vs those without. 18 The above findings notwithstanding, the links between the TaqI-A1 and -B1 alleles and smoking have not been consistently found. For example, higher prevalence rates of the TaqI-A1 or -B1 alleles in current and former smokers vs non-smokers were not found in a family-based analysis. 19 Additionally, a case-control study comparing MexicanAmerican lung cancer patients and controls did not find any relation between the TaqI-B1 allele and smoking behavior in lung cancer patients, although they did report an increased incidence of the TaqI-B1 allele in current vs never-smokers in the control group. 18 Association studies have traditionally been the first step in identifying candidate genetic markers for a particular phenotype, although these have often resulted in heterogeneous findings across studies and samples. These studies may differ because they often rely on gross characterizations of complex phenotypes and fail to capture behavioral variation among smokers with varying levels of dependence. Rather than focus on the presence or absence of a globally defined characteristic such as smoker vs non-smoker, specific behavioral phenotypes (i.e., endophenotypes) can be formulated in relation to genetic markers (i.e., 20, 21 ). Examples of specific endophenotypes include classifying smokers by their withdrawal symptom trajectories and variability over time, measured using daily diary data. [22] [23] [24] [25] Also, analyses of withdrawal and abstinence data gathered daily, rather than retrospectively, may yield more information about the circumstances in which some genes may exert their influence on smoking behaviors, given that the closer in time the assessment of smoking and withdrawal is to their actual occurrence, the greater the sensitivity at discerning the relationships between the two. 26 The current study used previously unpublished daily diary data from a recent study in our laboratory 27 investigating the role of the DRD2 TaqI-A polymorphism in smoking cessation. In that trial all smokers were provided with the nicotine patch plus brief counseling and were randomized to receive either placebo or venlafaxine, a non-selective serotonin reuptake inhibitor that inhibits the reuptake of serotonin and norepinephrine. In this previous study, average abstinence rates from the quit date to a one-year post-treatment follow-up indicated that smokers carrying the TaqI-A1 allele quit smoking significantly less often than those homozygous for the TaqI-A2, regardless of treatment condition. No interaction was observed between treatment and genotype for abstinence. However, a genotype by treatment interaction was observed for weekly ratings of negative affect, during treatment, which showed that only smokers homozygous for the TaqI-A2 allele manifested a reduction in retrospective ratings of negative mood, when receiving venlafaxine vs placebo. This suggests that examining withdrawal data, which have a significant affective component, 28 might provide additional data on cessation phenotypes, particularly if those assessments were measured frequently, such as those obtained in daily diary ratings.
For the present study, we focused on the relationship of the DRD2 TaqI-A and -B polymorphisms with short-term daily treatment outcome and withdrawal symptoms, collected from diary data, among smokers treated with venlafaxine or placebo. We were interested in using daily abstinence and withdrawal symptoms to identify potential endophenotypes of the DRD2 TaqI-A and the lesser-studied DRD2 TaqI-B polymorphisms and expected that these daily measures would provide us with more sensitivity to detect the impact of this polymorphism on smoking behavior than the weekly measures we previously reported. 27 We hypothesized that smokers with the at-risk TaqI-A1 or -B1 allele would be less likely to abstain, as measured by a daily diary of cigarette use, than those homozygous for the TaqI-A2 or -B2 allele. We also hypothesized that those with the at-risk allele (TaqI-A1 or -B1) would report greater withdrawal symptoms measured daily than those without these alleles. 16 ; the TaqI-A genotypes also met criteria for Hardy-Weinberg equilibrium as described in Cinciripini et al. 27 Owing to of the small number of B1/B1 genotypes, the B1/B1 and B1/B2 genotypes were combined into a single category of B1 carriers. A similar categorization was performed for the TaqI-A polymorphism. Smokers having the at-risk TaqI-A1 allele also had the TaqI-B1 allele 87.5% of the time, whereas smokers homogonous for the TaqI-A2 allele were homogonous for the TaqI-B2 allele 78.1% of the time.
Results

Allele frequency and genotype
Baseline participant characteristics As summarized in Table 2 , the sample was mainly white participants in their 40s who smoked more than a pack a day. No significant differences (P40.05) between genotype were found for any of the baseline measures in Table 2 . As excluding the small number of non-white participants (7.8%) did not affect gene frequency and did not alter the results described below, we report results that include the entire sample. For the pre-quit baseline, there was no main effect of either TaqI-A or -B genotype on any of the withdrawal measures (P's40.38).
DRD2 TaqI-A results
The current study investigated the effects of the TaqI-A1 allele on withdrawal symptoms and abstinence rates for only the first 42 days post-quit, using daily assessments and a scale specifically developed to measure symptoms of nicotine withdrawal. Contrary to our hypotheses, smokers with the TaqI-A1 allele did not show decreased daily abstinence rates or decreased Wisconsin smoking withdrawal scale (WSWS) or Minnesota Withdrawal Symptom Checklist (MWSC) withdrawal symptoms during this period than those without the allele. We found no interactions between the DRD2 TaqI-A polymorphism and any of the fixed factors (i.e., treatment, abstinence, baseline cigarettes and time) for either the daily abstinence or daily withdrawal measures.
DRD2 TaqI-B and abstinence
Following standard procedures used in clinical trials research, we analyzed a more conservative intent-to-treat Abbreviation: BMI, body mass index.
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sample, where missing daily diary data points were coded as smoking. Differential attrition was not observed, as no association was found between diary non-completion rates and the presence of either the DRD2 TaqI-A (P ¼ 0.81) or the TaqI-B (P ¼ 0.13) genotypes.
To evaluate whether the DRD2 TaqI-B genotype predicted abstinence, we examined whether genotype and its interactions with time and treatment predicted daily abstinence, whereas covarying baseline smoking rate (cigarettes/day), depression history (positive vs negative), sex and race. We found a significant TaqI-B Â time interaction, F(1,4754) ¼ 4.00, Po0.05, for daily abstinence rates. Figure 1 indicates that while both the B2/B2 and the at-risk B1 (B1/B1 or B1/ B2) groups were less likely to report daily abstinence over the course of the 6-week post-quit period, those smokers with the at-risk TaqI-B1 allele were less likely to report daily abstinence as the study progressed. No significant gene by treatment interaction was found (P ¼ 0.79). Venlafaxine produced no appreciable increase in daily abstinence rates for either the B2/B2 (OR ¼ 0.75, 95% CI ¼ 0.31, 1.82) or the at-risk B1 (OR ¼ 0.90, 95% CI ¼ 0.36, 2.24) group, compared to placebo.
DRD2 TaqI-B and withdrawal symptoms
The mixed model multivariate regression approach was used to examine the impact of DRD2 TaqI-B genotype on daily withdrawal symptoms as measured by the WSWS and the MWSC. Raw data from these scales were Z-score transformed across the post-quit days 0-41 observations to facilitate comparison between scales. The DRD2 TaqI-B genotype and its interactions with treatment, daily abstinence and time were examined, whereas covarying the corresponding mean baseline (À14 to À1 days pre-quit) WSWS or MWSC score, baseline smoking rate (cigarettes/day), daily abstinence, depression history (positive vs negative), sex and race. Significant DRD2 TaqI-B Â time interactions were found for several WSWS scales, including anger, F (1, 3854 Figure 2 indicate that those smokers with the B2/ B2 genotype tended to report fewer symptoms as a function of time. No interactions between TaqI-B genotype and either treatment or daily abstinence were found.
The main effects for depression history, treatment group and daily abstinence on WSWS and MWSC withdrawal scales are presented in Table 3 for the DRD2 TaqI-B subsample. Overall, these main effects indicated that being in the placebo group, having a history of depression, or relapsing led to greater absolute WSWS and MWSC scores during the 42 days post-quit compared to being in the drug group, having no history of depression, or abstaining from smoking, respectively. Neither sex, race, nor baseline smoking rate predicted withdrawal symptoms.
Discussion
We found that smokers carrying the DRD2 TaqI-B1 allele (i.e., B1/B1 or B1/B2) reported significantly more symptoms of daily smoking withdrawal over time. Regardless of treatment and daily abstinence status, smokers carrying the at risk TaqI-B1 allele reported significantly greater scores on the WSWS anger, anxiety, concentration, sadness, and sleep scales and the MWSC withdrawal measure during the first 42 days of smoking cessation compared to smokers homozygous for the TaqI-B2 allele (i.e., B2/B2), whose withdrawal symptoms significantly decreased over the same period. These effects were significant even though we covaried baseline withdrawal symptoms, baseline smoking rate, daily abstinence, depression history, sex and race.
The findings suggest that smokers with different DRD2 genotypes may exhibit distinct withdrawal trajectories, with smokers homozygous for the TaqI-B2 allele reporting progressive improvement in withdrawal symptoms while smokers with the TaqI-B1 allele showing little change. The examination of smoking withdrawal dynamics has received considerable attention in recent years and has yielded important findings relating withdrawal characteristics to smoking abstinence, lapse and relapse. 22, 24, 29, 30 Using withdrawal data from two clinical trials, Piasecki et al. 22 empirically identified three different profiles of withdrawal symptoms. They found that many smokers exhibited a typical withdrawal profile in which they reported a steady improvement of withdrawal symptoms (Profile 1). However, other smokers reported an atypical profile in which they experienced either an initial reduction of symptoms followed by a return to the original level of distress (Profile 2) or a fairly constant level of strong withdrawal symptoms throughout the course of a cessation attempt (Profile 3). Although the symptom trajectories reported by smokers homozygous for the TaqI-B2 allele is suggestive of a typical withdrawal profile, the trajectories reported by smokers with the TaqI-B1 allele resembles that of an atypical, unremitting profile. Figure 1 DRD2-B Â time interaction for daily abstinence, using the intent to treat sample, while controlling for treatment (venlafaxine vs placebo) as a between-subject fixed effect and the covariates baseline smoking rate (cigarettes/day), depression history (positive vs negative), sex and race. The figure depicts abstinence probabilities that were derived from predicted abstinence log odds. 
DRD2 TaqI-B and withdrawal
JD Robinson et al
To our knowledge, the current study is the first demonstration of a possible association between the DRD2 TaqI-B polymorphism and withdrawal trajectories. However, because the biological significance of the TaqI-B1 allele has not been fully explored, it is unclear what mechanisms may account for the relationship between genotype and withdrawal trajectory. Nevertheless, these results, if validated, may help to explain earlier findings regarding the relationship between the TaqI-B polymorphism and smoking. For instant, Spitz et al. 16 found that smokers with the TaqI-B1 allele made fewer lifetime attempts to quit than those without the allele. If smokers with the TaqI-B1 allele were more vulnerable to experience unremitting withdrawal symptoms during an initial attempt, they might be discouraged by their quit experience and became reluctant, should they relapse, to make new attempts in the future. Hence, B1 smokers may make fewer lifetime attempts to quit smoking.
We also found a significant relationship between the TaqI-B polymorphism and daily smoking abstinence, with smokers carrying the TaqI-B1 allele being increasingly less likely to be abstinent on a given day than those carrying the homozygous TaqI-B2 allele. Given the association between the TaqI-B polymorphism and withdrawal profiles, the reduced abstinence rate for TaqI-B1 smokers is consistent with previous findings that smokers with an atypical withdrawal trajectory are less likely to abstain from smoking. 22 That is, since smokers with the TaqI-B1 allele may not experience any improvement or relief of the negative withdrawal symptoms, they may become less successful in achieving abstinence when they make a quit attempt. Taken together, the results suggest that, despite therapy (nicotine patch, counseling and pharmacotherapy), at-risk B1 smokers experience a greater level of withdrawal symptoms over time and are less likely to abstain from smoking.
Unlike our earlier findings, 27 we failed to find a relationship between TaqI-A genotype and either short-term daily abstinence or daily withdrawal symptoms. However, owing to the different time periods sampled (42 days post-quit vs 1 year post-quit) and the different measures used (WSWS vs. PANAS) between the two studies, the results are not necessarily contradictory. In our earlier study, we measured abstinence and mood during weeks 1-6, 10, 18, 26, and 52 post-quit, 27 using seven-day point prevalence, whereas in the current study, measurement was taken daily for only the first 42 days (6 weeks) post-quit. According to our earlier findings, the majority of the weekly abstinence assessments during the first 6 weeks of the post-quit period showed only a small, possibly nonsignificant difference in abstinence rate between those with and without the TaqI-A1 allele. The largest difference occurred at week 10 when over 55% of smokers homozygous for the TaqI-A2 allele remained abstinent, compared to less than 40% of those carrying the TaqI-A1 allele. If smokers with and without the TaqI-A1 allele did not differ in their ability to quit until later in their post-quit period, our current analysis, given its short-term focus, would not necessarily reveal a significant difference in abstinence rates between the two groups. Furthermore, the longer duration and broader sampling points (i.e., over the past 7 days) used in the previous study may have captured more stable periods of abstinence than the daily, short-term fluctuations in abstinence captured by the current study. Similarly, the PANAS questionnaire used in our previous study asks about mood during the 'past week,' whereas the WSWS instructions ask about symptoms during the 'last 24 h.' Although there is some similar content between the scales, the PANAS scales were designed to measure two partially orthogonal affective dimensions, 31 whereas the seven WSWS scales were designed to capture nicotine withdrawal symptoms and roughly correspond to six of the eight symptoms listed in the Diagnostic and Statistical Manual (DSM)-IV. 32 The lack of any significant gene by treatment group interaction, particularly for abstinence rate, is not surprising for several reasons. First, we found no gene (TaqI-A) by treatment group interaction in our previous study. 27 Second, the sample size in this study was small, making it difficult to detect significant differences for the 2 Â 2 between-subjects interaction. Third, while venlafaxine may influence dopamine at the D2 receptor site by inhibiting reuptake of serotonin (and norepinephrine), the magnitude and duration of this effect on the D2 receptor have not been conclusively determined. Perhaps a marker for serotonin neuroregulation, such as the SERT (5-HTTPLR), may be a better candidate for study with venlafaxine than the markers of dopaminergic function we used in this study. This paper is limited by its single gene focus and the small sample size. Smoking is likely to be polygenetically determined, and isolation of a single gene provides only a limited amount of information. However, the ability to test for multiple genes requires a significantly larger sample than that used here. Future research may partly overcome sample size issues by using within-subject designs and including other physiological (e.g., electroencephalographic) or cognitive measures of nicotine withdrawal.
In summary, we showed that smokers with the TaqI-B1 allele are less likely to abstain from cigarettes during smoking cessation therapy. Given the strong LD between the TaqI-A and -B polymorphisms, the current findings may be viewed as complimentary to our earlier findings that TaqI-A1 smokers may have a more difficult time quitting smoking. 27 We also found that when TaqI-B1 smokers make a quit attempt, they may be more likely to experience an atypical withdrawal profile characterized by unremitting symptoms over time. The possible association between TaqI-B genotypes and withdrawal trajectories is important and warrants further examination. If confirmed, this association between genotypes and withdrawal profiles may have implications on the development of genotype-specific treatment strategies.
Materials and methods
Participants
Participants in this study were current smokers recruited for a double-blind placebo controlled clinical trial of the antidepressant venlafaxine. Characteristics of the full DRD2 TaqI-B and withdrawal sample (N ¼ 166) as well as treatment outcome data related to the effects of venlafaxine on smoking cessation have been described in another report. 33 The current paper involves an assessment of the effects of genotype on smoking cessation and smoking withdrawal symptoms, assessed daily, among the participants from the larger sample for which DRD2 TaqI-A (n ¼ 134) and DRD2 TaqI-B (n ¼ 131) genetic information was available. All smokers were volunteers recruited from the Houston, Texas, metropolitan area. To be included in this trial, smokers were required to smoke at least 10 cigarettes per day at baseline and to be 18-75 years of age. Smokers participating in any other smoking cessation treatment, currently taking other psychoactive medication or those having any uncontrolled systemic illness, contraindications for taking venlafaxine or the nicotine patch, current substance abuse or other psychiatric disorders were excluded. This research was approved by the University of Texas MD Anderson Cancer Center IRB.
Procedure
Participant screening, treatment and assessment procedures have been detailed in earlier reports 27, 33 but will be briefly summarized here. Smokers who met all inclusion criteria were stratified by gender and history of depression and randomly assigned to receive 20 weeks of either active venlafaxine (Effexor; Wyeth Pharmaceuticals, Madison, NJ, USA) or placebo. All participants also received brief smoking cessation counseling and nicotine replacement therapy (Prostep Nicotine Patch; Lederle Laboratories, Pearl River, NY, USA). Antidepressant therapy began 2 weeks before quitting, at an initial dose of 75 mg/day (37.5 mg/day b.i.d.). The dose was titrated for both active and placebo groups up to 150 mg/day in the week just before quitting. In each subsequent week, the dose was raised for both groups in 37.5 mg increments up to a maximum 225 mg/day. An increase in dosage was recommended for either group, if participants reported no side effects on their current dose and were either unable to remain abstinent and/or reported significant feelings of negative affect or other symptoms of nicotine withdrawal. Two weeks before the end of treatment (i.e., at 16 weeks post-quit), participants began tapering the medication, decreasing the dose by 37.5 mg every 2-3 days. The medication cycle was completed 18 weeks after quitting. All participants also used the nicotine patch (Prostep, Lederle Laboratories, Pearl River, NY; 22 mg) for 6 weeks, beginning on their quit-date.
A smoking cessation counseling treatment was provided concurrent with antidepressant therapy. Following the baseline visit, all smokers received six in-person and three telephone counseling sessions over the next 9 weeks. The content of the counseling sessions was a cognitivebehavioral approach similar to that used in our previous studies (e.g., 34, 35 ), and applied a standard coping skills training approach 36 to cessation and relapse prevention.
Assessments
Scheduled clinical interview for DSM-IV. The scheduled clinical interview for DSM-IV (SCID) is a widely used clinician administered interview that assesses the DSM-IV Axis I disorders. 37 The affective disorders section of the SCID was administered before randomization to assess current and past history of major depressive disorder.
Baseline nicotine dependence and smoking behaviors. The Fagerström test of nicotine dependence (FTND) is a 6-item measure used to assess nicotine dependence. 38 Baseline daily smoking rate was also collected by this instrument. It was administered before randomization.
Abstinence status. Participants recorded their daily cigarette intake each night in a diary before going to bed for 56 consecutive days, 14 pre-and 42 post-quit. The smokers were instructed to fill out the diaries before going to bed each evening, recording their cigarette use over the past 24 h, counting even a puff as a cigarette. The smoking diaries were collected by the staff during the weekly sessions that occurred during this period. Daily abstinence was calculated based on this smoking diary, with zero cigarettes defined as abstinent and all other responses, including missing, defined as non-abstinent. Seven-day point prevalence abstinence was verified before weekly treatment sessions using expired CO (p10 p.p.m.). Measures were obtained on four occasions during the post-quit diary period, including the quit date and during post-quit weeks 1, 3, and 6. When CO abstinence was compared to the daily smoking diary entry for each of the corresponding days, we found that a diary-reported claim of abstinence did not correspond to CO 5.86% of the time. As leaving out these observations or recoding them as smoking days did not alter the abstinence results presented below, we decided to retain them in our analyses without alteration. Weekly mood and abstinence assessments, collected before the treatment session, were conducted at weeks 1-6, 10, 18, 26, and 52 post-quit and are reported elsewhere. 27, 33 Wisconsin smoking withdrawal scale. The WSWS is a selfreport measure of nicotine withdrawal. It consists of the following seven subscales: anger, anxiety, concentration, craving, hunger, sadness and sleep. The WSWS mood and craving scales demonstrate increases as a function of nicotine abstinence. 32 The WSWS was administered for 56 consecutive days along with the smoking diary. Participants were given a packet of these questionnaires at each of the weekly sessions during this period and instructed to fill them out before going to bed each evening, rating their symptoms over the past 24 h.
Minnesota withdrawal symptom checklist. The MWSC consists of a 9-item list of tobacco withdrawal symptoms (i.e., desire to smoke (craving), anger/irritability/frustration, anxiety/ nervousness, difficulty concentrating, impatience/ restlessness, hunger, awakening at night and depression). 39 Items were rated on a 0-4 scale (none-severe) of symptom severity and are summed to create a withdrawal score. Participants completed the MWSC on a daily basis for 56 days as described above for the WSWS. Genotyping assay. DNA was extracted from whole-blood samples for polymerase chain reaction (PCR) analyses using standard phenol extraction methods. Genotyping for the DRD2 TaqI-A and -B polymorphisms followed the PCR method reported in one of our previous studies. 16 
Statistical analysis
The primary analytic strategy used a mixed model approach to examine the effects of genotype on repeated measures of abstinence and daily withdrawal. The mixed model approach provides a generalization to the classic linear regression model, using likelihood functions instead of least squares to estimate effects. 40 The mixed model approach is ideally suited for analysis of repeated measures data (i.e., growth curve modeling) in that it allows for estimates of the correlation structure of the residuals and efficiently handles unbalanced designs and missing data, without excluding participants or imputing values. 41, 42 We used PROC MIXED (SAS Version 9.1, SAS Institute Inc Cary, NC, USA) to estimate and test the models involving the measures of withdrawal. When abstinence was the dependent variable, we used SAS PROC GLMMIX, an adaptation of PROC MIXED that is suitable for the evaluation of a dichotomous outcome variable (abstinence). To facilitate comparisons between scales, WSWS scale and MWSC scores were standardized using a Z-scores transformation across all observations. Effect of genotype on abstinence. The effect of genotype on abstinence was evaluated using a model that included daily abstinence as the binary-dependent variable, genotype and treatment (venlafaxine vs placebo) as between-subject fixed effects, and time (post-quit days 0-41) as the repeated measures factor. Covariates included baseline smoking rate (cigarettes/day), depression history (positive vs negative), sex and race. Subject was modeled as a random effect. Separate models were tested to evaluate the effects of the DRD2 TaqI-A (A1/A1/A2 vs A2/A2) and -B (B1/B1/B2 vs B2/ B2) polymorphisms. The analyses for the effects of venlafaxine treatment (without regard to genotype) on smoking cessation have been previously reported for the larger sample and are not duplicated here. 33 A standard approach to model building was followed that included an initial assessment of main effects due to genotype, time (week of assessment) and treatment, followed by evaluation of the 2-way and 3-way interaction terms. Main effects were evaluated on the first iteration (e.g., genotype and time controlling for treatment) followed by the 2-way and 3-way interactions. F-statistics for all significant effects are reported, and for comparisons involving genotype and daily abstinence, odds ratios and confidence intervals (95% CI's) are also included.
Effects of genotype on daily withdrawal A multivariate regression mixed models approach was used to evaluate the effects of genotype on withdrawal symptoms during smoking cessation. 43 The effects of genotype on withdrawal measures were simultaneously evaluated using a model that included WSWS and MWSC scale scores as the continuous dependent variable, genotype (B1/B1 or B1/B2 vs B2/B2), daily abstinence (smoking vs abstinent) and treatment (venlafaxine vs placebo) as between-subject fixed effects, and time (post-quit days 0-41) as the repeated measures factor. Covariates included the corresponding mean baseline (À14 to À1 days pre-quit) WSWS score, baseline smoking rate (cigarettes/day), daily abstinence, depression history (positive vs negative), sex and race. Subject was modeled as a random effect. The residual error variances over time were modeled as a heteroscedastic random effect, using an autoregressive function, as a likelihood ratio test indicated that it improved model fit over the homoscedastic model.
The basic model for this analysis included genotype, treatment, time and their 2-way and 3-way interaction terms. Significant main effects and interactions related to genotype were further explored using a least-squares mean procedure to contrast pairwise differences among selected means participating in the effect. Each WSWS scale was analyzed separately. Similar analyses were performed on the MWSC scores. Nonlinear functions of time (e.g., quadratic and cubic functions) were modeled but were found to be nonsignificant and are not reported here. Separate analyses were conducted to evaluate the effects of the DRD2 TaqI-A (A1/A1 or A1/A2 vs A2/A2) and -B (B1/B1 or B1/B2 vs B2/B2) polymorphisms.
Analysis of demographic and baseline variables
Student's t-tests (continuous variables) and w 2 -tests (discrete variables) were used to examine differences on baseline demographic characteristics and mean WSWS and MWSC scale scores during the pre-quit baseline, by genotype.
